Skip to content
IVCC Welcomes Bayer’s New IRS Solution 11th January 2019

IVCC has welcomed the WHO Pre-Qualification of Bayer’s Fludora™ Fusion, combining different modes of action, as another major step forward in malaria control and insecticide resistance management.

IVCC supported the development of this new indoor residual spray (IRS) product in field trials where the product was tested against various resistant mosquito strains and on different relevant surface types. The data generated demonstrated that Fludora™ Fusion provides robust and consistent results, matching the needs of malaria control programs across Africa.

Nick Hamon, CEO of IVCC said: “We were pleased to have been able to support part of the Fludora™ Fusion trial program and to see this milestone achieved. New vector control tools are desperately needed to combat resistance and this is another positive addition to the toolbox.”

IVCC’s David McGuire who, with other consortium partners PMI, Abt Associates and PATH, leads the $65.1m Unitaid funded NgenIRS initiative, added: “Fludora™ Fusion will be a powerful and timely addition to the range of new indoor residual spray products implementing partners can use across sub-Saharan Africa.Following the successful deployment of Syngenta’s Actellic® 300 CS and Sumitomo’s SumiShield® we now have greater choice of new generation IRS products that can support sub-national rotation of insecticides, a major weapon against the threat of insecticide resistance. The introduction of more products from different manufacturers has also created a competitive environment for third generation IRS that is driving down prices to affordable levels for malaria control programs and their donor partners.

Dr. Jacqueline M. Applegate, Head of the Environmental Science business unit at Bayer added: “We are very proud to have achieved WHO Pre-Qualification for Fludora™ Fusion; it reflects our long-term commitment towards supporting the elimination of vector-borne diseases. It is a clear example of our focus on applying science to advance life – malaria control programs will now have access to an additional safe, efficient and cost-effective solution to protect the millions at risk from the disease.”

 

For further information, please contact:

Chris Larkin
Head of Communications and External Relations
IVCC
Phone: +44 151 702 9371
Mobile: +44 7712 402498
Email: christopher.larkin@IVCC.com(link sends e-mail)

About IVCC

IVCC is the only product development partnership (PDP) working in vector control. Established in 2005, IVCC works with stakeholders to facilitate the development of novel and improved public health insecticides and formulations and provides information tools to enable their effective use. IVCC’s vision is simply to save lives, protect health and increase prosperity by preventing insect-borne diseases. IVCC is funded by The Bill & Melinda Gates Foundation, UKaid, USAID, Unitaid, the Global Fund, the Australian Government and The Swiss Agency for Development and Cooperation.

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen.

NgenIRS at ASTMH, 2018 19th November 2018

The 67th Annual Meeting of the American Society of Tropical Medicine and Hygiene

Members of the NgenIRS project, along with a few thousand colleagues from around the world, met in New Orleans, LA for five days to share recent findings from world-class research on tropical medicine and hygiene, including malaria. Molly Robertson, Evidence lead for the NgenIRS project at PATH, along with Larry Slutsker, Director of Malaria and Neglected Tropical Diseases at PATH, co-chaired a symposium on indoor residual spraying (IRS) and drug-based malaria control. Symposium presenters reviewed observational evidence and modeling showing the benefits of combining IRS for malaria vector control with drug-based interventions, including mass drug administration (MDA) and seasonal malaria chemoprevention (SMC), for malaria parasite control. Diadier Diallo of MEASURE Evaluation presented research on IRS and SMC in the Segou Region of Mali showing that there was a 39 percent reduction in all-ages malaria incidence in areas that received both IRS and SMC compared to a 16 percent reduction in SMC areas and a 28% reduction in IRS areas. Other symposium presenters included Thom Eisele from Tulane University, Dorothy Echodu from Pilgrim Africa, and Ellie Sherrard-Smith from Imperial College.

NgenIRS partners from PATH also presented updated analyses on the cluster randomised control trial in Mopeia, Mozambique; the impact of introducing IRS in Mopti Region, Mali; and the reintroduction of IRS in Northern and Upper East Regions, Ghana. In Mozambique, preliminary results from active cohort surveillance based on spray status have shown a 17-month cumulative rate ratio of .81 (.77-.94). Interim analysis of case data from routine health systems reflect the same trends seen in infection data from the active cohort—a significant reduction in malaria incidence of approximately 19.4% to 25% in IRS vs. non-IRS clusters. In Ghana, preliminary analyses show clear correlations in time and space with indoor residual spraying of a 3GIRS product and reduced incidence of confirmed malaria cases from routine surveillance systems in the north of Ghana, where pyrethroid resistance is widely reported. Finally, in Mali, after introducing IRS into 4 districts of Mopti in 2017, rapid diagnostic testing (RDT)-confirmed malaria rates fell 37% compared to similar unsprayed districts. And after suspending IRS in Segou District in 2017, RDT+ confirmed malaria rates rose 125% compared to similar unsprayed districts. Final in-depth analyses on all of the aforementioned work will be forthcoming in 2019.

Symposium co-chairs and speakers show up in costume during the October 31st ASTMH session on combining IRS and drug-based interventions.

Sign up to receive the IVCC Newsletter